SERA · Sera Prognostics, Inc.
$1.96
-0.05 (-2.49%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Each of the foregoing factors may harm our business, operating results, and financial condition and may impact our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$77.32M
Shares
39.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.96
Open$2.01
Day$1.96–2.05
52W close$1.59–3.75
Avg vol 30d38K
Short int231K · 0.6% float · 6.4d
Short vol32%
Last earningsAug 12, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 19, 2026
Est · unconfirmed
· in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−2%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−20%
trailing
YTD return
−34%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +2 funds added
Insider flow
Distributing
Net -$87.3K over 90 days · 100% sells
Short interest
Falling
0.59% of float · ▼ -4.1% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
EPS growth
+32%
Y/Y
Free cash flow
$-26.3M
Balance sheet
$3.9M
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Base operating expenses
· annually
$10M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2023
Total 2024 gross cash expenses
· this year / 2024
$26M
Potential additional investment beyond gross cash expenses
· this year / 2024
up to $5M
Annual gross cash burn
· this year / 2024
up to $25M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +2 funds added
Insider flow
Distributing
Net -$87.3K over 90 days · 100% sells
Short interest
Falling
0.59% of float · ▼ -4.1% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 17%
Range high $4
vs 200-day avg -20%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SERA
this stock
Sera Prognostics, Inc.
|
$77.32M | -33.6% | +5.2% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SERA | -5.3% | -4.4% | -20.0% | -3.9% | -33.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.7% | -8.8% | -33.8% | -7.8% | -47.4% |
Key facts
CIK
1534969
CUSIP
81749D107
13F (30d)
46 filings
46 filers
Visit website
Investor relations